Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Kourlaba, Georgia ^a   Parissis, John ^b   Karavidas, Apostolos ^c   Beletsi, Alexandra ^d   Milonas, Charalambos ^e   Branscombe, Neil ^f   Maniadakis, Nikos ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d Servier Hellas Pharmaceuticals Ltd   (Greece)

^e NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^f INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cost effectiveness; Cost utility; Heart failure; Ivabradine

Indexed keywords

BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; IVABRADINE;

CHRONIC DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; GREECE; HEART FAILURE; HUMAN; LENGTH OF STAY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICS AND NUMERICAL DATA;

BENZAZEPINES; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; GREECE; HEART FAILURE; HUMANS; LENGTH OF STAY; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84965188979     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-014-0631-0     Document Type: Article

References (23)

1. Krum H, Stewart S: Chronic heart failure: time to recognize this major public health problem. Med J Australia 2006, 184:147-148.
2. Mosterd A, Hoes AW: Clinical epidemiology of heart failure. Heart 2007, 93:1137-1146.
3. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC: Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000, 83:505-510.
4. The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th edition. Boston: Mass: Little, Brown & Co; 1994.
5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Guidelines ESCCfP: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
6. Liao L, Allen LA, Whellan DJ: Economic burden of heart failure in the elderly. Pharmacoeconomics 2008, 26:447-462.
7. Kaye DM, Krum H: Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov 2007, 6:127-139.
8. Ivabradine for chronic heart failure? Drug Ther Bull 2012, 50:117-120.
9. Swedberg K, Komajda M, BohmM, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators S: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
10. Briggs A, Claxton K, Sculpher M: Decision modelling for health economic evaluation. New York: Oxford University Press Inc; 2006.
11. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M: The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart 2014.
12. National Institute of Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Process and methods guides. [http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-themethods-of-technology-appraisal-2013-pdf]
13. Kind P, Hardman G, Macran S: UK Population norms for the EQ-5D. York Centre for Health Economics Discussion Paper 1999, 172.
14. Greek Ministry of Health.s Diagnostic Related Groups. [http://www.yyka. gov.gr/articles/health/domes-kai-draseis-gia-thn-ygeia/kwdikopoihseis/709-kleista-enopoihmena-noshlia-1]
15. Greek Ministry of Health.s Drug price bulletin. [http://www.yyka.gov.gr/]
16. Government Gazzette: Presidential Decree 81/88, FEK 36/29-2-88 vol.A, "Costing of Medical Visits & Operations". Athens, Greece; 1988.
17. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B: Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health: J Int Soc Pharm Outcomes Res 2004, 7:518-528.
18. Devlin N, Parkin D: Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004, 13:437-452.
19. World Health Organization.: WHO Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. In Book WHO Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. City; 2001.
20. WHO: Choosing interventions that are Cost Effective WHO-CHOICE, Cost-effectiveness thresholds. Available at http://www.who.int/choice/costs/CER-thresholds/en/index.html, 2013.
21. IMF, 2012. International Monetary Fund, World Economic Outlook Database, October 2012. Available at http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx.
22. Briggs A, Claxton K, Sculpher M: Desicion modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
23. Fenwick E, O'Brien BJ, Briggs A: Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004, 13:405-415.